Market Place
Sourcing Support
Plus Therapeutics Restores Nasdaq Listing Compliance
26 Aug 2025 //
GLOBENEWSWIRE
Plus Therapeutics Meets Nasdaq Rule With $2.5M Equity
15 Aug 2025 //
GLOBENEWSWIRE
Plus Therapeutics Updates on US Launch of CNSide® Diagnostic
31 Jul 2025 //
GLOBENEWSWIRE
Plus Therapeutics Gets $1.6M Advance Payment from CPRIT
23 Jul 2025 //
GLOBENEWSWIRE
Plus Therapeutics Reveals REYOBIQ Results for Leptomeningeal
15 Jul 2025 //
GLOBENEWSWIRE
Plus Therapeutics to Present Two CNSide Studies at SNO/ASCO CNS
10 Jul 2025 //
GLOBENEWSWIRE
Plus Therapeutics Starts Trial for Leptomeningeal Metastases
08 Jul 2025 //
GLOBENEWSWIRE
Plus Gets FDA OK for ReSPECT-LM Dose Trial in LM
30 Jun 2025 //
GLOBENEWSWIRE
Plus Therapeutics Updates on CNSide Subsidiary
26 Jun 2025 //
GLOBENEWSWIRE
Plus Therapeutics to Host Business Update and Call on June 26
25 Jun 2025 //
GLOBENEWSWIRE
Plus Therapeutics FDA clears REYOBIQTM for Childhood Brain Cancer
25 Jun 2025 //
GLOBENEWSWIRE
Plus Therapeutics Announces $15M Equity Financing Restructuring
24 Jun 2025 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q1 Financial Results & Highlights
30 May 2025 //
GLOBENEWSWIRE
Plus Therapeutics Receives Nasdaq Deficiency Notice
23 May 2025 //
GLOBENEWSWIRE
Plus Therapeutics` Reyobiq Shows Benefit in ReSPECT-LM Trial
14 May 2025 //
GLOBENEWSWIRE
Plus Therapeutics to Join D. Boral Capital Global Conference
08 May 2025 //
GLOBENEWSWIRE
Plus Therapeutics: Kyle Guse Joins Board of Directors
23 Apr 2025 //
GLOBENEWSWIRE
Plus Therapeutics Presents New Data on REYOBIQ in ReSPECT-LM Trial
15 Apr 2025 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q4 and Full Year 2024 Financial Results
27 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Introduces Reyobiq as FDA-Accepted Name
20 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutic to Announce Q4 & Full Year 2024 Financial Results
19 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Regains Nasdaq Compliance On Equity Requirement
10 Mar 2025 //
GLOBENEWSWIRE
Plus Publishes Ph1 Rhenium-186 Data In Glioblastoma In Nature
07 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Gets FDA Orphan Drug Nod For Rhenium-186 In Lung Mets
06 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Announces New Employment Inducement Grants
05 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Secures $15M in Private Placement
04 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Advances Rhenium (186Re) Obisbemeda For LM
26 Feb 2025 //
GLOBENEWSWIRE
Plus Therapeutics Announces Leadership for CNSide Diagnostics
24 Feb 2025 //
GLOBENEWSWIRE
Plus Therapeutics Names Dr. Michael As Chief Development Officer
20 Feb 2025 //
GLOBENEWSWIRE
Plus Therapeutics Secures $5.7M To Support Leptomeningeal Program
18 Feb 2025 //
GLOBENEWSWIRE
Plus Therapeutics Presents Positive ReSPECT-LM Ph 1 Data at SABCS
17 Dec 2024 //
GLOBENEWSWIRE
Plus Therapeutics Showcases ReSPECT-LM Ph 1 Data at SABCS 2024
04 Dec 2024 //
GLOBENEWSWIRE
Plus Expands Agreement with Telix for Rhenium-186 Supply
03 Dec 2024 //
GLOBENEWSWIRE
Plus Presents Phase 1 Data for Leptomeningeal at SNO Conference
25 Nov 2024 //
GLOBENEWSWIRE
Plus Presents Positive FORESEE Trial Summary on CNSide™ Assay
22 Nov 2024 //
GLOBENEWSWIRE
Plus Therapeutics to CNSide Assay Data in Leptomeningeal Metastases
21 Nov 2024 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q3 2024 Financial Results & Highlights
14 Nov 2024 //
GLOBENEWSWIRE
Plus Therapeutics & SpectronRx Announce Radiotherapeutic Deal
06 Nov 2024 //
GLOBENEWSWIRE
Plus Therapeutics to Announce Q3 Results & Host Call on Nov 14
05 Nov 2024 //
GLOBENEWSWIRE
Plus Therapeutics Showcases Leptomeningeal Programs at SNO 2024
29 Oct 2024 //
GLOBENEWSWIRE
Plus Therapeutics Updates ReSPECT-GBM Trial at Neurosurgeons Meeting
01 Oct 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents ReSPECT-GBM Data At CNS Meeting
18 Sep 2024 //
GLOBENEWSWIRE
Plus Therapeutics To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q2 2024 Financial Results And Business Highlights
14 Aug 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents Trial Results At SNO/ASCO Conference
13 Aug 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents ReSPECT-LM Phase 1 Data At SNO/ASCO
12 Aug 2024 //
GLOBENEWSWIRE
Plus Therapeutics To Announce Q2 Results On August 14, 2024
08 Aug 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents Leptomeningeal Metastases Data At SNO/ASCO
25 Jul 2024 //
GLOBENEWSWIRE
Plus Therapeutics To Present At Gordon Research Conference
02 Jul 2024 //
GLOBENEWSWIRE
Plus Expands Management, Reports $3.3M CPRIT Payment
06 Jun 2024 //
GLOBENEWSWIRE
Plus Therapeutics Announces New Employment Inducement Grants
17 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q1 2024 Results, Business Highlights
15 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics To Announce Q1 Results, Host Call On May 15
13 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics LM Acquisition, FORESEE Trial Topline Data
09 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics Investor Call On Acquisition, FORESEE Data
08 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
06 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics Gets $3M DoD Award Recommendation
22 Apr 2024 //
GLOBENEWSWIRE
Plus Thera to Present at the National Comprehensive Cancer Network Conference
27 Mar 2024 //
GLOBENEWSWIRE
Plus Announces Validation & Clinical Implementation of CSF-01
25 Mar 2024 //
GLOBENEWSWIRE
Plus Therapeutics Completes Dosing in Phase 1 Trial of Rhenium
11 Mar 2024 //
GLOBENEWSWIRE
